Towards erythropoietin mimicking small molecules

'Atypical Ugi' tetrazoles

Amino acid-derived isocyano amides together with TMSN3, oxocomponents and 1° or 2° amines are common substrates in the Ugi tetrazole reaction. We surprisingly found that combining these substrates gives two different constitutional isomeric Ugi products A and B. A is the expected classical Ugi product whereas B is an isomeric product ('atypical Ugi') of the same molecular weight with the tetrazole heterocycle migrated to a different position. We synthesized, separated and characterized 22 different isomorphic examples of the two constitutional isomers of the Ugi reaction to unambiguously prove the formation of A and B. Mechanistic studies resulted in a proposed mechanism for the concomitant formation of A and B.

Pseudo five-component synthesis of bis-alpha-acyloxy-beta-diketo amides from diimide-dicarboxylic acids

Diimide-dicaboxylic acids derived from condensation of alpha-amino acids with the 2,3,5,6-bicyclo[2.2.2] oct-2-enetetracarboxylic-2,3:5,6-dianhydride or 1,2,4,5- bezenetetracarboxylic-1,2:4,5-dianhydride react with ninhydrin and isocyanides to produce some novel interesting bis-alpha-acyloxy-beta-diketo amides.

Complexity in biomaterials for tissue engineering

The molecular and physical information coded within the extracellular milieu is informing the development of a new generation of biomaterials for tissue engineering. Several powerful extracellular influences have already found their way into cell-instructive scaffolds, while others remain largely unexplored. Yet for commercial success tissue engineering products must be not only efficacious but also cost-effective, introducing a potential dichotomy between the need for sophistication and ease of production. This is spurring interest in recreating extracellular influences in simplified forms, from the reduction of biopolymers into short functional domains, to the use of basic chemistries to manipulate cell fate. In the future these exciting developments are likely to help reconcile the clinical and commercial pressures on tissue engineering.